En del af Watch Medier

MedWatchfredag3. februar 2023

  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Søg
  • Log ind
  • Seneste
  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
16.10.2013kl. 12.15

Analyst: New Novo drug to clear path for game-changer

The newly approved haemophilia drug Novoeight has potential to generate multimillions in sales, says an analyst, but its main purpose is to clear a path for another pivotal Novo drug.
by Stefan Singh Kailay

It is all about getting a chunk of the market with this new drug - which might not be a game-changer, but nevertheless has some attractive qualities – and gain a position on the market, before launching the long-acting drug that might turn out to be the real game-changer within the field.

That is the basic situation for Novo Nordisk following Wednesday’s FDA approval of haemophilia drug Novoeight, according to Sydbank analyst Søren Løntoft Hansen.

“Novoeight isn’t a game-changer, but the drug does have some positive qualities, e.g. that the patient does not form antibodies. That’s very positive, also compared with other drugs. Novo has to go and slug it out with other players  and carve out a chunk of the market – for example, Baxter’s Advate, which is the head honcho,” he tells Medwatch, elaborating:

Should be room

“There should be room for Novoeight on the market one way or another, if they are able to convince patients and doctors of the advantages from switching to Novo’s drug, based – for example – on the fact that it doesn’t lead to the formation of antibodies.”

In addition, the Danish company could focus on its injection device, MixPro, which seems to be slightly more convenient to use than current products.

“It is my impression that other current products require a bit more preparation in connection with the injection.”

The real game-changer

So for Novo, the real task is to get a footing on the market.

“Hopefully they will land a long-acting version, which will be the real game-changer in this market, within a number of years.”

US rival, Biogen Idec, is slightly ahead of Novo in this regard with its drug Eloctate, for which FDA accepted a registration application in May this year. Novo’s similar product, N8GP, is still in phase III.

“But we can see from the available data that it looks like Novo’s drug has a longer lasting effect,” the analyst says.

Søren Løntoft Hansen has a global peak sales estimate of DKK 3-4bn (USD 544-725m) for Novoeight, based on Novo conquering a 15 % share of the market for severe cases of haemophilia A.

 Novo’s younger sibling has growing pains 

 Analysts: This is where Novo can stand out 

 Novo Nordisk: Turoctocog is just the first step 

 Novo: We want to be to hemophilia, what we are to diabetes 

- translated by Martin Havtorn Petersen

Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.

Relaterede artikler:

  • Foto: Novo Nordisk PR

    Novo’s younger sibling has growing pains

    For abonnenter

  • Foto: Novo Nordisk

    Analysts: This is where Novo can stand out

    For abonnenter

  • Foto: Novo Nordisk/PR

    Novo Nordisk: Turoctocog is just the first step

    For abonnenter

Tilmeld dig vores nyhedsbrev

Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.

!
Nyhedsbrevsvilkår

Forsiden lige nu

John Haurum, bestyrelsesformand i Solid Therapeutics | Foto: John Haurum / Privat
Medicinal & Biotek

Navneskift skal skabe investorinteresse for kræftselskab

Efter forskningsmæssige fremskridt skifter biotekselskabet Warburg Oncology navn og udpeger i samme øvelse en adm. direktør, der blandt andet får til opgave at rejse kapital fra private investorer. 
  • Nystiftet kræftselskab får erfaren biotekprofil som formand

For abonnenter

Anders Kühnau, formand for Danske Regioner | Foto: Rikke Kjær Poulsen / Ritzau Scanpix
Medicinal & Biotek

Danske Regioner klar med anbefalinger til kortere sagsbehandlingstider i Medicinrådet

For abonnenter

Foto: Stine Tidsvilde
Medicinal & Biotek

Novo Nordisk vil fastholde medarbejdere med aktiegave til 35.000 kr

For abonnenter

Stifterne af medtech-virksomheden Ward 24/7, som sidste år fik en investering fra finske Innovestor, der er klar til at investere i flere danske virksomheder. Her ses Ward 24/7's adm. direktør Betina Langemark (i midten), flankeret af medstifterne Christian Meyhoff (tv.) og Eske Aasvang (th.) | Foto: Ward 24/7 / PR
Medicinal & Biotek

Finsk venturefond ser mod Danmark for investeringer i life science

Foto: Mike Blake/Reuters/Ritzau Scanpix
Medicinal & Biotek

Eli Lilly løfter forventningerne til 2023

Foto: Michael Buholzer
Medicinal & Biotek

Roche forudser mindre salg og indtjening fra coronamidler i 2023

Seneste nyt

  • Navneskift skal skabe investorinteresse for kræftselskab – 06.58
  • Finsk venturefond ser mod Danmark for investeringer i life science – 2. feb.
  • Danske Regioner klar med anbefalinger til kortere sagsbehandlingstider i Medicinrådet – 2. feb.
  • MSD tjener mere end ventet i fjerde kvartal – 2. feb.
  • Novo Nordisk vil fastholde medarbejdere med aktiegave til 35.000 kr – 2. feb.
  • Roche forudser mindre salg og indtjening fra coronamidler i 2023 – 2. feb.
  • Eli Lilly løfter forventningerne til 2023 – 2. feb.
  • Analytikere: Kerneforretningen driver Ambus organiske vækst – 2. feb.
  • Efter sløv start haler diabetestablet fra Novo Nordisk ind på topsællert – 2. feb.
  • Medicinrådet er stadig for langsomme til at vurdere ny medicin – 2. feb.
  • Dansk Erhverv har lavet en ny life science-politik: Vi kan nå endnu længere, hvis vi justerer rammevilkårerne – 2. feb.
  • Boehringer Ingelheim flytter dansk hovedkvarter til Islands Brygge – 2. feb.
  • Fluoguide skifter finansdirektør efter få måneder – 2. feb.
  • Sydbank ser kinesisk modvind give afdæmpet start på året for Coloplast – 2. feb.
  • Jyske om Demant-regnskab i næste uge: Fokus bliver på forventningerne til 2023 – 2. feb.
Flere nyheder

Job

  • Application Manager

  • Regulatory Affairs Professional

  • Senior Clinical Project Manager

  • Medical Advisor (Metabolism)

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Commercial Director

  • Supply Chain Manager

  • Sr. Director, Drug Safety Physician

  • Erfaren Patentrådgiver

  • Senior Regulatory Affairs Professional

  • Lead Data Architect

  • Specialist til udbud på lægemidler til danske sygehuse

  • Head of Regulatory Affairs Danmark

  • Application Manager

  • Clinical Operational Associate

Se flere jobs

Watch Job

  • Salesforce-udvikler eller -arkitekt

  • Tilbudschef - NCC Renovering Vest

  • Scrum Master with a practical approach

  • Jurister søges til Corporate Legal i Danmarks Eksport & Investeringsfond

  • Business Controller til DAHL Advokatpartnerselskab i Jylland

Se flere jobs

Job

  • Application Manager

  • Regulatory Affairs Professional

  • Senior Clinical Project Manager

  • Medical Advisor (Metabolism)

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Commercial Director

  • Supply Chain Manager

  • Sr. Director, Drug Safety Physician

  • Erfaren Patentrådgiver

  • Senior Regulatory Affairs Professional

  • Lead Data Architect

  • Specialist til udbud på lægemidler til danske sygehuse

  • Head of Regulatory Affairs Danmark

  • Application Manager

  • Clinical Operational Associate

Se flere jobs

Kolofon

MedWatch
Søg

Sektioner

  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
  • Sitemap
  • RSS feeds

Redaktør

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tlf.: +45 3330 8387

Ansv. chefredaktør

Anders Heering

Udgiver

JP/Politikens Hus A/S

Annonceafdeling

annoncering@infowatch.dk

Tlf.: +45 7077 7441

Annoncering

Jobannoncering

job@infowatch.dk

Tlf.: +45 7077 7441

Job

Abonnement

Prøv MedWatch gratis eller få tilbud på et abonnement, der passer til lige netop dig eller din virksomhed.

medwatch@infowatch.dk

Tlf.: +45 7077 7441

Læs mere om abonnement her

Adresse

MedWatch

Rådhuspladsen 37

1785 København V

Tlf.: +45 3330 8370

Retningslinjer

  • Persondatapolitik

Copyright © MedWatch — Alt materiale på denne side er omfattet af gældende lov om ophavsret

Microsoft er i gang med at udfase Internet Explorer – det er vi derfor også.
Vi anbefaler en af følgende browsere for en bedre oplevelse. Klik på et af ikonerne for at downloade en ny browser.

Med venlig hilsen,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge